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Abstract 
Minimizing perioperative blood loss during orthopedic surgery has proven challenging for 
providers.  Perioperative utilization of antifibrinolytic pharmacologic interventions, such as 
tranexamic acid (TXA), has been demonstrated as a safe and effective technique for decreasing 
blood loss and allogenic blood transfusion rates.  Currently, the Food and Drug Administration 
(FDA) approved on-label indications of TXA are for use in short-term treatment of hemophilia 
patients undergoing dental extractions and in management of patients experiencing menorrhagia 
(Mayeux, Alwon, Collins, & Hewer, 2016).  Despite the current limited scope of FDA approval 
for TXA, use in elective surgery with otherwise clotting-uncompromised patients is not a new 
concept.  Perioperative TXA administration in elective joint replacement surgery, 
cardiopulmonary bypass, spinal fusions, and hysterectomies has been well studied (Duncan et al., 
2015).  Numerous studies have acknowledged TXA use decreases perioperative blood loss, 
decreases perioperative blood transfusions, and shortens length of hospital stay.  Additionally, 
research exists that demonstrates safety and efficacy of TXA use in patients presenting with 
traumatic injury (Roberts et al., 2013).  Despite this vast body of knowledge, little research exists 
evaluating TXA use in hip fractures.  Over 325,000 traumatic hip fractures occur every year 
(Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014).  This patient population is 
generally frail and typically lacks optimization prior to urgent surgery.  Based on the extensive 
body of prior research conducted to date, it is reasonable to postulate that TXA use in these 
instances would yield a decreased blood loss and therefore contribute to lower rates of allogenic 
blood transfusion in hip fracture patients.  
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Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures 
 
Introduction 
 
Finding new and innovative methodologies to reduce surgical blood loss is a major area 
of interest among orthopedic surgeons.  Over the past two decades a variety of techniques 
ranging from blood salvage systems to pharmacologic approaches have been examined as means 
to accomplish this goal and reduce the number of allogenic blood transfusions required during 
and after orthopedic surgical procedures.  In recent years, employment of pharmacologic 
methods has become increasingly popular.  Specifically, administration of an antifibrinolytic 
agent during the perioperative period has been proven to be an effective means of decreasing 
intraoperative bleeding.  The reduction of intraoperative bleeding is expected to confer a benefit 
to the patient by reducing the need for allogenic blood and blood product transfusions as well as 
the sequale associated with such transfusions (Das, Vijay, Bedi, & Mitra, 2013).   One 
antifibrinolytic in particular, tranexamic acid (TXA), has been well studied for use in scheduled, 
elective orthopedic surgery with heavy emphasis on total hip arthroplasty (THA) and total knee 
arthroplasty (TKA) (Charoencholvanich & Siriwattanasakul, 2011).  TXA is a lysine amino acid 
derivative that prevents break down of the fibrin clot.  TXA competitively binds to plasminogen.  
This competitive binding action obstructs naturally occurring lysine from binding with 
plasminogen thus preventing the formation of the enzyme plasmin.  Inhibition of the conversion 
of plasminogen to plasmin preserves the formed fibrin clot thereby decreasing blood loss at the 
site of bleeding or injury via clot stabilization (Vijay, Bedi, Mitra, & Das, 2013).   
Despite the over 325,000 hip fractures currently occurring each year in the United States 
and with hip fracture rates projected to increase each year reaching an estimated 500,000 per 
year in 2040 (Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014), research examining 
TRANEXAMIC ACID AND HIP FRACTURES  
 
4 
the efficacy of utilizing TXA in hip fracture surgery is quite limited.  Recent studies have 
generally been conducted on a relatively smaller scale and been limited to scheduled, elective 
procedures.  The focus of these studies has centered primarily on the ability of TXA 
administration to reduce overall blood loss, examination of the incidence of adverse thrombolic 
vascular occlusive events associated with the administration of TXA, or both.  In 
supplementation to these findings, The CRASH-2 Trial: A Randomized Controlled Trial and 
Economic Evaluation of the Effects of Tranexamic Acid on Death, Vascular Occlusive Events 
and Transfusion Requirement in Bleeding Trauma Patients (CRASH-2) study by Roberts et al. 
(2013), reviewed later in this paper, provides high quality evidence suggestive of both the safety 
and efficacy of TXA use in patients presenting with traumatically sustained injuries and 
otherwise normal coagulation profiles.   
While there is substantial high quality evidence supporting both the safety and efficacy of 
TXA use to reduce overall blood loss and need for allogenic blood transfusions during both 
scheduled orthopedic joint procedures as well as traumas, a limited quantity of research exists in 
support of administration of TXA to traumatic hip fracture patients (Roberts et al., 2013). These 
patients are not optimized for surgery and are therefore considered fragile and potentially more 
vulnerable during the postoperative period. Administration of an antifibrinolytic agent to reduce 
blood loss in patients who have sustained traumatic hip injuries has the potential to greatly 
improve patient outcomes. 
This lack of high quality peer reviewed evidence prompted the organization of such a 
research study to be conducted at Central Maine Medical Center (CMMC).  Central Maine 
Medical Center is located at 300 Main Street in Lewiston, Maine. The hospital serves most of 
Androscoggin County, Maine and various small and medium-sized communities (Central Maine 
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Medical Center, n.d.).  CMMC is a 300-bed, Level-II trauma center which preforms over 9,000 
surgeries annually (Central Maine Medical Center, n.d.).  CMMC is a teaching affiliate of 
Boston University School of Medicine as well as University of New England College of 
Osteopathic Medicine (Central Maine Medical Center, n.d.).   
Currently, a research proposal (please see Appendix A for the entire proposal) has been 
created, submitted to, and approved by the IRB at CMMC (please see Appendix E for approval 
letter).  This paper will examine the literature reviewed to construct the proposal, an outline of 
the study methods and goals, as well as a progress update.  All materials generated for 
submission to the IRB, IRB applications, patient handouts, informed consent literature, and 
approval documentation are attached in the appendices of this paper (Appendix B, C, and D). 
Literature Review 
TXA is a lysine amino acid derivative that aids in the prevention of the break down of 
existing clots.  TXA competitively binds to plasminogen preventing the formation of the enzyme 
plasmin.  By blocking the conversion of plasminogen to plasmin, the fibrin clot is stabilized and 
continues to exist thus decreasing the amount of blood lost at the site of injury or surgical 
incision (Napolitano, Cohen, Cotton, Schreiber, & Moore, 2013).  Currently, TXA is only 
approved by the US Food and Drug Administration (FDA) in oral short term use for patients 
with hemophilia needing dental surgery and for the treatment of menorrhagia (Mayeux, Alwon, 
Collins, & Hewer, 2016).  However, antifibrinolytics are actively being used off label in multiple 
types of surgery including cardiopulmonary bypass, elective total joint replacements, ear, nose, 
and throat (ENT), and spinal fusions. 
Because TXA disrupts the normal process of clot dissolution, safety questions around its 
use regarding a potential increase in the incidence of thromboembolic events have emerged.  
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Consideration of patient safety is of paramount concern when proposing or initiating research on 
human subjects.  Initial research results examined discussed the potential for increased adverse 
vascular occlusive events that may be associated with TXA administration to patients with an 
intact clotting profile.  The largest of these studies was The CRASH-2 Trial: A Randomized 
Controlled Trial and Economic Evaluation of the Effects of Tranexamic Acid on Death, Vascular 
Occlusive Events and Transfusion Requirement in Bleeding Trauma Patients (CRASH-2) study 
conducted by Roberts et al. (2013).  This level I evidence, multicenter, randomized, placebo-
controlled study examined the administration of TXA to “adult trauma patients with or at 
significant risk for bleeding and were within eight hours of injury undergoing surgical 
intervention to address their injuries and/or cause of bleeding” (Roberts et al., 2013, p. 1).  In this 
study 10,096 adult trauma patients were administered a one gram loading dose of TXA over 10 
minutes and started on an infusion of one gram of TXA over eight hours within eight hours of 
sustaining their traumatic injury.  For control comparison, 10,115 patients were administered 
normal saline in the same manner.  As previously stated, CRASH-2 is one of the largest studies 
conducted to date examining the potential effects of TXA administration.  CRASH-2 assessed 
the use of TXA in trauma patients with the goal of reducing death rates due to uncontrolled 
bleeding.  Results from CRASH-2 showed a significant decrease in bleeding following trauma 
and ultimately determined that the administration of TXA to trauma patients yielded a decrease 
in the observed death rate.  The mortality rate observed in the TXA group was 4.8% compared to 
6.1% in the placebo group.  Additionally, CRASH-2 revealed that TXA safely decreased the risk 
of death without increasing the risk of vascular events.  The rate of a vascular occlusion, such as 
a myocardial infarction, deep vein thrombosis, or pulmonary embolism, was 1.7% for patients 
that received TXA and 2% for those who received the placebo (Roberts et al, 2013). 
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   Ultimately, this study concluded that administration of TXA within three hours of 
initial injury “safely reduced the risk of death in bleeding trauma patients and (TXA) is highly 
cost-effective” (Roberts et al., 2013, p. 1).  Furthermore, CRASH-2 helped establish TXA as an 
essential medication on the World Health Organization’s (WHO) list.  The WHO list of essential 
medications declares certain medications should be available in ample amounts at affordable 
pricing due to their proven safety and efficacy as demonstrated by use with positive outcomes on 
a large number of patients (Roberts et al., 2013). 
Duncan et al. (2015) conducted a single center retrospective cohort study demonstrating 
the safety of TXA administration to patients with normal coagulation profiles.  Individual 
orthopedic surgeons within the institution had been using TXA on a patient-by-patient basis 
when they determined a potential benefit was present.  The orthopedic department on the whole 
came to the conclusion TXA offered a benefit to the majority of the patients undergoing joint 
surgeries.  A protocol for its routine use was established.  The institution sought positive 
affirmation that TXA was a safe and effective means to reduce bleeding during scheduled 
orthopedic procedures and approved the study proposed by Duncan et al. (2015).  Patients 
included in this study were undergoing either an elective THA or TKA.  Patient data over a 5-
year period was collected, collated, and examined to determine if administration of TXA 
contributed to an increased incidence of untoward vascular occlusive events.  Duncan et al. 
(2015) concluded “the overall frequency of clinically significant (venous thromboembolism) 
VTE was lower when TXA was administered, and the odds of postoperative VTE were 
unchanged” (Duncan et al., 2015, p. 275).  As additional positive support to the primary study 
finding, the authors noted “no statistically significant change was seen in 30-day mortality, 
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although a trend toward reduced mortality with TXA administration was observed” (Duncan et 
al., 2015, p. 275).   
Having found evidence in support of the safety of TXA use in both scheduled as well as 
trauma surgeries, the search expanded to examine current evidence attesting to the efficacy of 
perioperative TXA administration.  One such study consisted of a large meta-analysis looking at 
amicar, tranexamic acid, and aprotinin (Zufferey et al., 2006).  No significant increase in 
thromboembolic events stemming from the use of these three antifibrinolytic therapies was found 
during this study.  These results serve to corroborate the safety of administration of 
antifibrinolytic agents during surgical procedures reported by other studies. Additionally, all 
three antifibrinolytics showed a decrease in the amount of surgical blood loss and there was a 
concomitant decrease in the rate of allogenic blood transfusions required in the postoperative 
period.  Zufferey et al. (2006) found that aprotinin and tranexamic acid specifically decrease 
blood loss and blood transfusion rates when administered during the perioperative period in 
orthopedic surgery. 
Vijay, Bedi, Mitra and Das (2013) examined the ability of TXA to reduce perioperative 
blood loss during scheduled orthopedic procedures.  They focused their study solely on the use 
of TXA in patients undergoing hip fracture surgery.  Patients were either a physical classification 
status I or II between the ages of 18 and 80.  Of the 90 participants in this study, 45 were 
randomized into the test group and received TXA while 45 were randomized into the control 
group and did not receive TXA.  Primary outcomes for this study included examination of the 
volume of blood in the patients surgical site drain postoperatively, percentage of hemoglobin fall 
on postoperative day zero and day two, and allogenic blood transfusion rates.  The blood volume 
output into the surgical site drains for the TXA group was 39.33 +/- 10.09 mL compared to 91.11 
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+/- 17.61 mL in the control group.  Hemoglobin drop in the TXA on day zero was 2.99 +/- 3.45 
mL compared to the control group of 7.70 +/- 6.05 mL.  On postoperative day two, TXA 
hemoglobin drop was 0.35 +/- 0.74 g/dL and the control group was 2.72 +/- 2.7 g/dL.  Eighteen 
of the 45 patients in the control group received an allogenic blood transfusion while only seven 
out of 45 patients in the TXA group required transfusion (Vijay et al., 2013).  The level I 
evidence presented by Vijay et al. (2013) demonstrated the ability of TXA administration in the 
perioperative period to be an effective means to reduce postoperative blood loss and realize a 
reduced transfusion requirement for patients during major hip surgeries. 
In a 2011 Cochrane Review, the safety and efficacy of TXA was addressed (Henry et al., 
2011).  A placebo was compared to TXA when examining the rate of allogenic blood 
transfusions and adverse vascular events.  A total of 4,842 patients were randomized into either 
the placebo/control group or the TXA group.  Patients who received TXA saw a reduction in the 
rate of allogenic blood transfusions by 39%.  There was no increased risk of patients 
experiencing a thromboembolic event including stroke, deep vein thrombosis, myocardial 
infarction, pulmonary embolism, or development of renal disease reported in this study.  Henry 
et al. (2011) also showed there was no correlation between an increase in mortality and the use of 
TXA.    
Pongcharoen and Ruetiwarangkoon (2015) made conclusions similar to Duncan et al. 
(2015).  In their paper, a prospective controlled study was performed to examine the total amount 
of surgical blood loss experienced as well as the incidences of adverse vascular occlusive events 
experienced by their study participants.  Patients in this study were followed for a minimum of 
12 months in an effort to determine if the potential for delayed untoward vascular events existed.  
While patients in the TXA group of this study were found to have experienced lower amounts of 
TRANEXAMIC ACID AND HIP FRACTURES  
 
10 
intraoperative blood loss, this result was not statistically significantly.  More germane to the 
context of the research being conducted at Central Maine Medical Center, this level I evidence 
study demonstrated that patients in both the TXA group as well as the control group “did not 
present the clinical signs of (deep venous thrombosis) DVT and (pulmonary embolism) PE.  
They also did not show other thromboembolic events including cerebral vascular accidents or 
myocardial infarctions” (Pongcharoen & Ruetiwarangkoon, 2016, p. 7).  This study continues to 
support the safety profile of TXA use in patients with uncompromised coagulation profiles. 
Numerous level I, II, and one level III quality of evidence studies have examined the 
concomitant reduction of blood loss and safety of TXA administration to patients undergoing 
orthopedic procedures.  Poeran et al. (2014) conducted a retrospective cohort study of 510 
hospitals in the United States looking at patients undergoing elective TKA or THA.  Patients 
were grouped into those who received TXA in any form or dose versus those that did not.  
Poeran et al. (2014) found that TXA was an effective pharmacological intervention for the 
reduction in the need for allogenic blood transfusions while it did not produce an increased risk 
for adverse vascular complications in patients receiving the drug. 
Hart et al. (2014) examined the incidence of transfusion rates for over 23,000 patients 
that received either a total knee arthroplasty or a total hip arthroplasty.  Patients in this study did 
not receive an antifibrinolytic agent of any kind.  Allogenic blood transfusion rates were found to 
be as high as 22% for total hip arthroplasty and 18.3% for total knee arthroplasty (Hart et al., 
2014). Transfusion rates were deemed high given the number of patients in this study.  
Additionally, Hart et al. (2014) determined the mortality rate was increased in those patients who 
did receive a transfusion.  Due in part to these findings as well as countless others like it, 
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administration of TXA in elective joint replacement surgery has now become routine due to the 
high incidence of allogenic transfusion rates.     
In a randomized, double blind study involving 99 patients timing of TXA administration 
in total knee arthroplasty patients was examined (Tanaka et al., 2001). Tanaka et al. (2001) 
sought to determine the time for TXA administration that would achieve the greatest reduction in 
blood loss.  They determined that administration prior to incision and again once the tourniquet 
was deflated showed the greatest reduction in perioperative blood loss.  Regardless of the timing 
of administration, Tanaka et al. (2001) indicated there was a 40% decrease in blood loss after the 
administration of TXA.  Additionally, there was no reported increase in thromboembolic events 
observed during this study.  These findings once again support the safety as well as the efficacy 
of TXA administration.   
Blood loss continues from the time of injury throughout the perioperative period.  Blood 
oozes from the ends of cut bone, open intra-medullary canals, and from soft tissue after 
dissection (Sepah et al., 2011).  Over a three-year period patients undergoing a total knee 
arthroplasty were randomized into two groups:  those who received TXA or those who received 
a placebo.  Postoperatively, recipients of TXA experienced a mean blood loss from their drain of 
826-1,288 mLs whereas the placebo group experienced drainage of 1,828-2,695 mLs.  Once 
again, these findings present evidence that advocates for the use of TXA to decrease patient 
blood loss during the perioperative period.  None of the patients in the Sepah et al. (2011) study 
experienced problematic vascular events from the use of TXA.  This finding is supportive of the 
safety of TXA.  
One of the major motivating factors behind seeking methods to control perioperative 
blood loss is the potential need for patients experiencing high levels of surgical blood loss to 
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require allogenic blood transfusions during the perioperative period.  Zhang, Chen, Chen, and 
Que (2011) conducted a systematic literature review study examining 15 randomized control 
studies encompassing 842 patient outcomes.  Zhang et al. (2012) determined that administration 
of TXA during the perioperative period reduced the total blood loss and reported that the risk of 
transfusion was reduced by 56% due to the administration of TXA.  Further, the use of TXA did 
not yield an increase in the risk of deep vein thrombosis when administered to patients with an 
intact clotting profile undergoing TKA (Zhang et al., 2012).  Other similar studies also 
considered the benefit of giving TXA to reduce perioperative bleeding during TKA and THA to 
determine if a reduction in the number of perioperative allogenic blood product transfusion could 
be achieved with positive outcomes.  One retrospective quality of care chart review comparison 
of data before vs. after implementation of a TXA administration protocol found that data 
collected supported the perioperative administration of TXA due to its ability to reduce the 
number of blood transfusions required while not increasing the number of observed adverse 
vascular events (Baker et al., 2015).  Baker et al. (2015) reported that as the utilization of TXA 
increased from 45.8% to 95.3% in patients undergoing TKA the rate of allogenic transfusions 
required in patients during the postoperative period was reduced from 8.8% to 5.2%.  While 
findings presented by Baker et al. (2015) is level III evidence, Gandhi, Evans, Mahomed, & 
Mahomed (2013) presented level I evidence in support of utilization of TXA in the perioperative 
period to realize a reduction in the number of postoperative allogenic blood transfusions.  
Patients undergoing both THA as well as TKA were included in this Cochrane Review by 
Gandhi et al. (2013).  Specific interventions were very similar; all patients in the study test 
groups were intravenously administered TXA in either variable doses ranging from 10-15 mg/kg 
or 500-1,500 mg fixed doses prior to incision (Gandhi et al., 2013).  Gandhi et al. (2013) 
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demonstrated that the number of patients receiving allogenic transfusions was less in the TXA 
groups when compared to the control groups.  Additionally, there was no increase in the number 
of patients developing deep vein thrombosis or other untoward thromboembolic complications in 
the TXA groups as compared to the control groups.  This study, once again, offered high quality 
evidence supporting both the safety and efficacy of TXA in addition to its ability to realize a 
statistically significant reduction in the number of allogenic blood product transfusions required 
to be given to patients undergoing scheduled orthopedic joint procedures. 
Lee, Freeman, Edmondson, & Rogers (2015) examined 305 patients who underwent a 
total hip arthroplasty.  In this study, the efficacy of TXA administration to decrease perioperative 
blood loss and allogenic blood transfusions was examined.  Lee et al. (2015) reported data on 
over 300 patients who received a total hip arthroplasty and were randomized into either those 
who received TXA or the control group who did not receive TXA.  It was found that those who 
received TXA experienced a lower transfusion rate.  Transfusion rates were 6% in patients that 
received TXA and 19% in patients that did not receive TXA.  Hemoglobin was also measured 
preoperatively and postoperatively in these patients.  Postoperative hemoglobin dropped by 26% 
in the patients that received TXA and 42% in the non-TXA control group.  The patients that 
received TXA exhibited a large reduction in both transfusion rates and overall drop in 
hemoglobin level.  Henry et al. (2015) estimated that the use of TXA prevents one blood 
transfusion per every eight patients, thus supporting the routine use of TXA in orthopedic 
surgery.  
Charoencholvanich and Siriwattanosakul (2011) examined the duration of action of TXA. 
They sought information about its ability to help decrease blood loss and blood transfusion rates 
in the postoperative period. Therapeutic levels of TXA were detected in peripheral blood 
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samples for up to eight hours following administration.  This coincides with the duration of 
hyperfibrinolysis that can last up to eight hours following any kind of injury or trauma. 
Hyperfibrinolysis is an increased state of clot dissolution following disruption of normal 
homeostasis.  Homeostasis is disrupted as soon as injury occurs or surgical incision occurs.  
Additionally, 65% of blood drainage happens in the first eight hours following surgery.  
Charoencholvanich and Siriwattanosakul (2011) randomized 100 patients undergoing a total 
knee arthroplasty into two groups.  One group received a placebo and the second group received 
a bolus of TXA.  Both groups received standard treatment prior to incision and again after 
deflation of the tourniquet.  Postoperative drainage was estimated to be 1,208mLs +/- 421mLs in 
the placebo group and 727mLs +/- 234mLs in the group that received TXA.  The number of 
patients requiring an allogenic blood transfusion was decreased by 56-90% with the 
administration of TXA (Charoencholvanich & Siriwattanosakul, 2011).  These findings again 
support the use of TXA in orthopedic surgery to aid in decreasing the requirement for blood 
product transfusions.    
Administration of TXA is also being used in joint revision surgery, as these procedures 
tend to have a greater blood loss due to increased manipulation during removal of the existing 
hardware.  After mobilization and removal of old hardware, new hardware then needs to be 
placed, increasing the potential blood loss.  Samujh, Falls, Wessel, Smith, & Malikani (2014) 
examined TXA administration solely in total knee arthroplasty revisions.  Their research found a 
clinically significant decrease in allogenic blood transfusion rates in the patient group receiving 
TXA.  The control group in this study, as a whole, used 25 units of blood whereas the TXA 
group required the use of only three units of blood.   Also the transfusion rate reported in the 
control group was 30.3% compared to 16.7% in the TXA receiving group.  This clinically 
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significant observed decrease in blood transfusion rate again supports the perioperative 
administration of TXA.  Untoward vascular events were documented in this study.  
Thromboembolic events occurred in 3% of patients from the control group (2 out of 68 patients) 
and 2% (1 out of 43 patients) of patients in the TXA group (Samujh et al, 2014).  While an 
unfortunate occurrence contributing to overall morbidity, the incidence of vascular events 
reported was higher in the control group versus the TXA group suggesting it was not the 
administration of TXA that contributed to the reported events. 
Review of Dosing Strategies 
Having found significant amounts of high quality evidence within the current body of 
literature to support the safety of administration of TXA to patients, as well as extensive 
literature to support the use of TXA as a means to reduce overall perioperative blood loss, the 
dosing strategy for the proposed study required determination of an appropriate evidence based 
schedule and amount of drug to be administered.  George, Sarraf, & Nwaboku (2015) examined 
the effect of TXA dose timing on the perioperative total blood loss as well the rate of allogenic 
blood transfusion and incidence of thromboembolic complications.  Secondarily, the cost of 
utilizing the drug was also considered.  While this study also focused on primary THA and TKA, 
the underlying safety information as well as their findings related to the timing of the 
administration of TXA are what was most relevant to the proposed study at Central Maine 
Medical Center.  Patients in the George, Sarraf, & Nwaboku (2015) study “who received TXA 
showed a reduction in immediate postoperative red cell volume loss and total blood loss” 
(George, et al., 2015, p. 129).  Because of this finding, the primary conclusion of this study was 
that “a single perioperative bolus of intravenous TXA may significantly reduce operative blood 
loss” (George et al., 2015, p. 129) in a cost-conscious manner.  Additionally, George et al. 
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(2015) cited the successful use of TXA in the CRASH-2 study on trauma patients to reduce 
bleeding and also went on to discuss the large body of scientific publications that “have 
confirmed the efficacy of TXA in significantly reducing operative blood loss and reducing the 
need for postoperative blood replacement” (George et al., 2015, p. 129).   
Similar to George et al. (2015), Sarzaeem et al. (2014) also examined a variety of dosing 
schedules and manners of administration of TXA in an effort to reduce perioperative blood loss.  
Sarzaeem et al. (2014) conducted a level I evidence study including patients 18 years of age and 
older undergoing unilateral TKA due to degenerative arthritis of the knee.  Unlike other studies, 
patients in this study were not excluded due to prior cardiovascular issues, cerebrovascular 
conditions or a history of thromboembolic disorders.  Patients in this study were allocated to 
groups using a random number list system.  Groups were labeled 1-4.  Group 1 received 
1,500mg of TXA via intravenous injection just prior to incision.  Group 2 had the joint 
undergoing replacement irrigated with three grams of TXA dissolved into 100mL of normal 
saline.  Group 3 had 1,500mg of TXA injected into the drain port after surgical closure had been 
achieved.  Group 4 was the control group and had no TXA of any kind administered.  Sarzaeem 
et al. (2014) found that the administration of TXA by any method does indeed reduce bleeding as 
evidenced by a reduction in the overall level of hemoglobin decrease.  The intravenous injection 
of TXA appeared to be considerably more efficacious than the irrigation of the joint or wound 
drainage port, and that all groups did realize a reduction in bleeding when compared to the 
control group (Sarzaeem et al., 2014).   
Gomez-Barrena, Ortega-Andreu, Padilla-Eguiluz, Perez-Chrzanowska & Figueredo-
Zalve (2014) examined the difference between topical intra-articular TXA and intravenous TXA 
in reducing blood loss during total knee arthroplasty.  Results showed the two routes of 
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administration to be equally efficacious in regard to the amount of total blood loss and blood 
drainage postoperatively.  TXA levels were measured in the peripheral blood postoperatively. 
When peripheral blood levels of TXA were taken during the postoperative period, the intra-
articular group exhibited a TXA level significantly lower than what was observed in the 
intravenous TXA group.  Administration of topical TXA gave the same results as intravenous 
TXA administration in terms of decreasing blood loss and drained blood. However topical 
administration of TXA significantly reduces the risk of thromboembolic occurrence by 
decreasing systemic circulation of TXA (Gomez-Barrena et al., 2014).  
According to Meyeux et al. (2016), when TXA is used to reduce blood transfusion rates, 
large institutional cost savings can be realized and potentially passed along to patients.  The cost 
of one unit of packed red blood cells to the patient is $343 compared to $45-55 for one gram of 
TXA.  Additionally, blood products may be limited in their availability making administration of 
TXA even more desirable.  Routine TXA administration, unless contraindicated, has the 
potential to drastically improve resource allocation.  Administration of TXA decreases the cost to 
the patient and also serves to reduce the morbidity and mortality that is a potential result from 
blood product administration (Meyeux et al, 2016).  
Contraindications to receiving TXA have been put into two categories:  absolute 
contraindications and relative contraindications (Meyeux et al., 2016).  Color blindness, 
hypersensitivity to TXA, active intravascular clotting and subarachnoid hemorrhage are 
considered absolute contraindications.  Evaluation for TXA toxicity is preformed through an eye 
exam.  The ophthalmic exam is only useful to detect TXA toxicity in patients who have 
functioning color vision.  In patients who are color blind, providers are not able to distinguish if 
TXA toxicity exists and must therefore not be administered TXA (Meyeux et al., 2016).  History 
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of a vascular occlusive event, administration of a procoagulant therapy, or hormonal 
contraceptive use is considered to be relative contraindications for the use of TXA (Meyeux et 
al., 2016).  
 Blood loss in hip fractures starts at the time of injury and continues throughout the 
perioperative period.  Foss (2006) concluded that total intraoperative blood loss from a hip 
fracture is up to six times the amount observed.  Hidden blood loss of 547-1,473 mLs contributes 
to patient complications postoperatively.  Large blood loss during surgery in a vulnerable elderly 
population drastically increases medical complications and increased length of hospital stay 
(Foss, 2006).    
 Shokoohi et al. (2012) examined the effects of hip fracture surgery and blood transfusions 
on the elderly population.  Shokoohi et al. (2012) concluded that blood transfusions did not 
confer an increase in mortality but was associated with an increase in postoperative infections 
following hip fracture surgery.  Mortality was measured at postoperative day 28 and 180.  No 
difference in transfused versus non-transfused patients was reported.  Bleeding is associated with 
any type of fracture however in this specific postoperative population, even small amounts of 
blood loss put these patients at risk for hypovolemia and anemia. Transfused patients also have 
an increase in length of hospital stay when compared to those patients who did not receive 
transfusions (Shokoohi et al, 2012).  Shokoohi et al. (2012) serves as support for utilizing TXA 
as a means of decreasing transfusion rates in the frail elderly population experiencing hip 
fractures as an effort to reduce infection rates and decrease length of hospital stay.   
Zufferey et al. (2010) studied the use of TXA in hip fracture surgery as a means to reduce 
blood loss.  One hundred and ten patients participated in the study.  Patients received one dose of 
TXA prior to incision and a second dose three hours later.   The rate of allogenic blood 
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transfusion was 42% in the TXA group as compared to 60% in the control group (Zufferey et al., 
2010).   A slightly increased incidence of adverse vascular events reported in this study however, 
this increase was not statistically significant (Zufferey et al., 2010).   
Discussion:  Study at Central Maine Medical Center 
The number of hip fracture occurrences in the United States is increasing every year, with 
the majority of hip fractures happening in a vulnerable elderly patient population.  Hip fracture in 
this population is associated with a mortality rate of 7-14% while still in the hospital and reaches 
14-36% within a year of surgery (Mundi, Pindiprolu, Simunovic, & Bhandari, 2014).   An 
increased risk of death is associated with a hip fracture and persists for up to six years post injury 
(Yonezawa, Yamazaki, Atsumi, & Obara, 2009).  Factors contributing to the risk of death within 
six years of fracture are:  preoperative health status, pre-fracture mobility, age, sex and 
comorbidities (Yonezawa et al, 2009).  Common comorbidities in this population are dementia, 
congestive heart failure, coronary heart disease, previous myocardial infarction, renal failure, 
chronic lung disease, and diabetes (Neuman, Rosenbaum, Ludwig, Zubizarreta, & Silber, 2014).  
Mortality after hip fracture is linked to a decrease in postoperative mobility that is associated 
with a simultaneous decline in overall health status and quality of life (Mundi et al, 2014).  Up to 
half of all hip fracture patients do not regain their pre-fracture functionality.  Additionally, 20% 
of hip fracture patients require some form of long-term care due to the inability to preform 
activities of daily living and decreased mobility (Tajeu et al., 2013).   
For the nine-month period ending on September 30th, 2016, CMMC is experiencing a 19% 
transfusion rate for patients undergoing surgical repair of hip fractures in their facility.  This 
compares to a 1.5% transfusion rate for primary elective hip replacement surgeries where TXA is 
being administered prophylactically during the perioperative period.  As discussed above in the 
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literature review presented, administration of antifibrinolytic therapy during the perioperative 
period has been offered as a means to decrease intraoperative bleeding.  The reduction in 
intraoperative bleeding is assumed to confer a benefit to the patient by reducing the need for 
infusion of and sequale associated with allogenic blood and blood product transfusions.  The 
primary objective of the CMMC study is to determin if the use of TXA reduces perioperative 
blood loss and therefore reduces the need for allogenic blood transfusion in patients undergoing 
surgery to repair hip fracture.  Secondary objectives of this study will examine calculated blood 
loss between the TXA and placebo groups, determination if the reduction in allogenic blood 
transfusion imparts a parallel reduction in the incidence of complications such as infection, 
length of hospital stay, and death.  Additionally, we seek to determine if use of TXA in this 
patient population imparts an increased risk of adverse vascular events and/or death.  Should data 
indicate any such increased risk, the study will be terminated prior to scheduled completion and 
all current study participants will be notified.   
To take part in this prospective, randomized, double-blinded, off label trial study at CMMC, 
patients are required to meet certain inclusion criteria.  Patients must be greater than 65 years of 
age.  Patients must present with an acute, traumatic hip fracture sustained after a fall from 
standing.  Patients who acquired their hip fractures after high impact collisions are excluded 
from participation.  Patients must freely provide their informed consent.  Additionally, patients 
meeting inclusion criteria for this study must be without history of treatment with 
anticoagulation agents, vascular events such as stroke, myocardial infarction, pulmonary 
embolism, deep vein thrombosis, or a clotting disorder.  Patients presenting with an unknown 
medical history, or if a full medical history cannot be obtained, may not be included in the study.   
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Patients may be enrolled into the study by one of the study’s Clinical Research Coordinators.  
The Principal Investigator, Co-Principal Investigator, Sub-Investigators, or Clinical Research 
Coordinators are able to obtain informed consent from prospective patients or their legal 
representative.  When patients enter the facility with a hip fracture via the Emergency 
Department, the registered nurse (RN) House Supervisor will alert the Clinical Coordinator to 
their arrival.  This will trigger the Clinical Coordinator to review the patient’s history and 
physical, demographics, and nature of their injury.  Should the patient meet the inclusion criteria, 
outlined in the above paragraph, the Clinical Research Coordinator may approach the patient to 
consent them for enrollment into the study.  Once informed consent has been obtained, a Clinical 
Research Coordinator will then personally deliver the consent to the pharmacy where the consent 
will be secured in a locked filing cabinet.  Sarah Green, PharmD will be unblinded in this study.  
She will produce randomized kits in the CMMC Inpatient Pharmacy numbered from one to 125.  
Randomized TXA and placebo kits will be created in batches of 20.  Half of the kits will contain 
TXA and half will contain placebo.  As patients are added to the study, the Inpatient Pharmacy 
will dispense the kits based on the patient’s number of entry into the study.  When a patient is 
enrolled into the study by a Clinical Research Coordinator, they will be sequentially added to the 
study list and tracked by FIN number within the Inpatient Pharmacy by Sarah Green.  No 
personal identifier will be used in the randomization.  No one participating in the study, patient 
or provider, will have access to identifying information enabling him or her to determine which 
patients are receiving active drug vs. placebo.  Thus meeting the definition of calling a study 
double blinded.  Participants in the placebo group will be administered 100 mL of normal saline 
15 minutes prior to skin incision.  Participants in the intervention group will be administered 
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1,000 mg tranexamic acid reconstituted into 100 mL of normal saline 15 minutes prior to skin 
incision.  
A wide variety of dosages and timing regimes for a single perioperative dose of TXA 
were examined throughout the literature search and review.  The findings presented by George et 
al. (2015) were utilized to determine the most efficacious timing for the dose of TXA to be 
administered to the traumatic hip population being examined in the CMMC study.  George et al. 
(2015) determined a single 1,000 mg dose of TXA would confer the previously reported benefit 
of reduced bleeding.  This is a simplified and conservative dosing schedule that has been shown 
to reduce bleeding and was therefore chosen due to both its simplicity as well as its demonstrated 
efficacy.  
In the postoperative period all patients will have vital signs and hemoglobin and hematocrit 
levels monitored per institutional standards of care.  Vital signs will be checked every four hours 
and laboratory values will be checked daily, or more frequently at individual provider discretion.  
Patients meeting institutional requirements for a blood transfusion during either the 
intraoperative or postoperative period will be considered for the primary outcome.  As stated in 
our hypothesis in Appendix A:  IRB Application, we expect the pre-incision administration of 
TXA will reduce the rate of intraoperative and postoperative allogenic blood transfusion.  
The patient’s independent medical team on the institution’s Hospitalist service will determine 
the need for and if criteria are met for blood transfusion.  CMMC protocol requires patients meet 
certain requirements prior to receiving allogenic red blood cell transfusion.  In the setting of 
active bleeding institutional requirements for red blood cell transfusion include: acute blood loss 
of >25% of blood volume unresponsive to fluid resuscitation, acute blood loss with a 
hemoglobin of <9g/dL with moderate to severe cardiovascular disease, or a decrease in 
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hemoglobin level of 2g/dL within 24 hours with a hemoglobin of less than 8g/dL or hematocrit 
less than 24g/dL with signs or symptoms of anemia.  Signs or symptoms of anemia are defined 
as fatigue, pallor, shortness of breath, lightheadedness, heart rate >100 beats per minute, and lab 
values revealing hemoglobin and hematocrit levels less than 9g/dL and 24g/dL respectively.  As 
previously stated, an independent medical team will follow patients who require transfusion of 
blood products.  Patients will receive post transfusion evaluation of hemoglobin and hematocrit 
levels at time intervals determined to be medically necessary by the hospitalist or surgeon 
responsible for their care.  Typically, patients will receive daily checks of hemoglobin and 
hematocrit level until they are able to maintain a stable hemoglobin level >7g/dL and hematocrit 
level >21g/dL in the absence of the signs or symptoms of anemia previously described. 
Patients participating in this study will be allowed to ambulate in the same manner as all 
other orthopedic surgical patients.  Postoperative weight bearing will be allowed as tolerated.  
DVT prophylaxis will follow standard hospital procedure.  Patients will receive 5,000 units of 
subcutaneous heparin on admission and every eight hours thereafter until 12 hours prior to 
surgery.  Six hours post surgical intervention, patients will resume heparin therapy.  
Additionally, when patients are not participating in physical rehabilitation activities, sequential 
calf compression devices shall also be utilized to further reduce the risk of developing DVT.   
Determination of blood loss will be calculated in the manner described below. 
• Estimated blood volume (EBV) preop: weight in kg * average blood volume mL/kg 
o Adult men: 75mL/kg 
o Adult women: 65 mL/kg 
• Multiplying the estimated blood volume by the hematocrit gives the red cell volume. 
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• Performing the calculation preoperatively and postoperatively then computing the 
difference calculates pre-operative vs. post-operative changes in red cell volume. 
o Pre-op RBC volume = EBV * pre-op Hct  
o Post-op RBC volume = EBV * post-op Hct 
o Operative RBC volume loss = Pre-op RBC volume – Post-op RBC volume 
Infection at the site will be characterized and reported per institution protocol.  Adverse 
vascular events that may be considered include myocardial infarction as diagnosed by a 
cardiologist based on ECG changes, elevated biological markers (creatine kinase, troponin), or 
echocardiogram changes and symptomatic DVT verified by ultrasound venography, pulmonary 
embolism confirmed by CT scan of the chest, pulmonary angiography, echo-cardiologic 
visualization or visualization of thrombus at autopsy. 
This study has been approved by the IRB at Central Maine Medical Center to run for one 
years time with a goal N=125.  Should the number of patients enrolled for outcome examination 
fail to be achieved in the approved timeframe, application for extensions will be considered on a 
yearly basis by the IRB.  To date, there have been 12 patients enrolled into the study. Data will 
be collected and examined on a quarterly basis.  The first gathering of raw data is to occur at the 
end of  March 2017.  Given the considerably lower than expected number of patients willing and 
able to be enrolled into the ongoing study, the Central Maine Medical Center research team is 
currently reexamining the schedule for data collection and review.  Currently, deliberation 
continues regarding what would represent the most efficient and productive time schedule to 
convene and assess data collected to date. 
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Conclusion 
A multitude of recent and high quality studies that have been conducted validate the efficacy 
and safety of TXA administration.  A wide range of patient populations presenting with varied 
surgical needs were examined within each of these research studies.  Results have shown that 
without question, use of TXA during a variety of scheduled orthopedic procedures has been 
revealed as an effective means to decrease blood loss during the perioperative surgical period 
(Zufferey et al. 2006).  The reduction of intraoperative bleeding is assumed to confer a benefit to 
the patient by reducing the need for infusion of, and sequale associated with, allogenic blood and 
blood product transfusions (Das et al. 2013).  However, a significant gap in current literature 
exists.  Very few recent high-quality studies examine administration of TXA to hip fracture 
patients.  Of those, Zufferey et al. (2010) is perhaps the most germane to the study currently 
being conducted at Central Maine Medical Center.  Zufferey et al. (2010) examined the rates of 
allogenic blood transfusion after two doses of TXA, as discussed above in the literature review 
section of this paper.  This study utilized a small number of patients, N=100, and showed a non-
statistically significant increase in the number of adverse vascular events.  The limitations of the 
Zufferey et al. (2010) study were its small size, limited duration, and inability to determine with 
any statistical importance if an increase in adverse vascular occlusive events can be seen when 
administering TXA to patients undergoing surgery for correction of a traumatic hip fracture.  The 
study underway at CMMC plans to address these two shortcomings of the previously conducted 
study by Zufferey et al. (2010).      
The ongoing study being conducted out of Central Maine Medical Center aims to provide 
high-quality evidence to support the use of TXA in the traumatic hip fracture population.  This 
will be done by increasing the number of patients examined from the N=100 cases considered by 
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Zufferey et al. (2010) to N=125.  The increase in sample size will increase the power of any 
hypothesis testing done at the completion of the study.  The duration of the study is currently 
approved for one year however, may be easily extended with submission of a renewal 
application to the CMMC IRB.  Given the expedited approval received after submission of the 
initial application, it is expected renewal and extension will not be an issue.  The CMMC study 
utilizes a single dose of TXA and is expected to improve overall patient outcome through the 
reduction of blood loss while concomitantly maintaining a low level of vascular sequale that may 
be attributed to the use of an antifibrinolytic therapy in the setting of trauma. 
Numerous studies, as discussed in detail above, support the use of TXA in elective joint 
replacement surgery to decrease perioperative blood loss.  Some of these studies also 
demonstrate that TXA administration decreases blood transfusion rates, length of hospital stay, 
and cost to the patient. Patients undergoing elective orthopedic surgery have been medically 
optimized to achieve the most successful outcomes.  Patients who have sustained a traumatic hip 
fracture may not be optimized and are therefore more likely to be considered fragile given their 
age, trauma status, preoperative baseline health, and presence of perioperative blood loss.  When 
considering these factors, decreasing blood loss during the perioperative period and reducing the 
need for allogenic transfusion is likely to realize improved postoperative outcomes in this patient 
population.  
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Appendix A 
 
 IRB Application 
 
Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures 
 
 
List of Abbreviations: 
 
TXA: Tranexamic Acid 
CMMC:  Central Maine Medical Center 
DVT:  Deep Vein Thrombosis  
LOS:  Length of Stay 
ENT:  Ear Nose and Throat 
 
Principal Investigator, Research Team, and Study Site: 
 
Principal investigator:  Morgan Guerrette 
Co-Principal Investigator:  Katherine Balzano-Cowan 
Clinical Research Coordinators:  Tina Moring, Sarah Green, James Osgood, Elizabeth 
Turcotte, Jay Bachelder, Robyn Begin, Carie Whitmore, Maija Comeau, and Diane Jeselskis 
Study site:  Central Maine Medical Center 
 
Study Information: 
 
Study Title:  Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures 
Study Population:  Any patient greater than 65 years of age presenting with traumatic hip 
fracture 
Study Design 
Sample Size:  n=125 
Study Duration:  1 year 
Study Agent:  Tranexamic acid  
 
 
Primary Objective:  Determination if the use of TXA reduces perioperative blood loss and 
therefore reduces the need for allogenic blood transfusion in patients undergoing surgery to 
repair hip fracture.   
 
Secondary Objectives:   
Secondary objectives of this study will examine calculated blood loss between the TXA and 
placebo groups, determination if the reduction in allogenic blood transfusion imparts a 
concomitant reduction in the incidence of complications such as infection (defined below), LOS, 
and death.  Additionally, we seek to determine if use of TXA in this patient population imparts 
an increased risk of adverse vascular events (defined below) and death. 
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Intervention Description:  Study participants will be assigned to either the placebo group or the 
intervention group.  Participants in the placebo group will be administered 100mL of normal 
saline 15 minutes prior to skin incision.  Participants in the intervention group will be 
administered 1,000mg tranexamic acid reconstituted into 100mL of normal saline 15 minutes 
prior to skin incision.   
 
All patients will have vital signs and hemoglobin and hematocrit levels monitored per 
institutional standards of care.  Patients meeting institutional requirements for a blood 
transfusion (see below) during either the intraoperative or postoperative period will be 
considered for the primary outcome.  We expect the pre-incision administration of TXA will 
reduce the rate of intraoperative and postoperative allogenic blood transfusion.  
 
The patient’s independent medical team will determine the need for and if criteria are met for 
blood transfusion.  CMMC protocol requires patients meet the following requirements prior to 
receiving allogenic red blood cell transfusion: 
 
In the setting of active bleeding a patient must have: 
 
1) Acute blood loss of >25% of blood volume unresponsive to fluid resuscitation 
Or 
2) Acute blood loss with a hemoglobin of <9 with moderate to severe cardiovascular disease 
Or 
3) A decrease in hemoglobin level of 2gm/dL within 24h with a hemoglobin of less than 
8/hematocrit less than 24 with signs or symptoms of anemia 
 
An independent medical team will follow patients receiving transfusion of blood products.  
Patients will receive post transfusion evaluation of hemoglobin and hematocrit levels at time 
intervals determined to be medically necessary by the hospitalist or surgeon responsible for their 
care.  Typically, patients will receive daily checks of hemoglobin and hematocrit level until they 
are able to maintain a stable hemoglobin level >7 and hematocrit level >21 in the absence of 
signs or symptoms of anemia. 
 
Patients participating in this study will be allowed to ambulate in the same manner as all other 
orthopedic surgical patients.  Postoperative weight bearing will be allowed as tolerated.  DVT 
prophylaxis will follow standard hospital procedure.  Patients will receive 5,000 units of 
subcutaneous heparin on admission and every 8 hours thereafter until 12 hours prior to surgery.  
6 hours post surgical intervention patients will resume heparin therapy.  Additionally, when 
patients are not participating in physical rehabilitation activities sequential calf compression 
devices shall also be utilized to further reduce the risk of developing DVT.   
 
Blood loss will be calculated using the following: 
• Estimated blood volume (EBV) preop: weight in kg * average blood volume mL/kg 
o Adult men: 75mL/kg 
o Adult women: 65 mL/kg 
• Multiplying the estimated blood volume by Hct gives the red cell volume 
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• Performing the calculation preoperatively and postoperatively then computing the 
difference calculates pre-op vs. post-op changes in red cell volume. 
o Pre-op RBC volume = EBV * pre-op Hct  
o Post-op RBC volume = EBV * post-op Hct 
o Operative RBC volume loss = Pre-op RBC volume – Post-op RBC volume 
 
 
Infection at the site will be characterized per institution protocol.  
 
Adverse vascular events may be considered: 
• Myocardial infarction as diagnosed by a cardiologist based on ECG changes, elevated 
biological markers (CK, troponin), or echocardiogram changes.  
• Symptomatic DVT verified by ultrasound venography, pulmonary embolism confirmed 
by CT scan of the chest, pulmonary angiography, echo-cardiologic visualization or 
visualization of thrombus at autopsy. 
 
Background and Significance: 
 
As of Q3 2016, CMMC is experiencing a 19% transfusion rate for patients undergoing surgical 
repair of hip fractures in our facility.  This compares to a 1.5% transfusion rate for primary 
elective hip replacement surgeries where TXA is being administered prophylactically during the 
perioperative period. 
 
Administration of antifibrinolytic therapy during the perioperative period has been presented as a 
means to decrease intraoperative bleeding.  The reduction in intraoperative bleeding is assumed 
to confer a benefit to the patient by reducing the need for infusion of and sequale associated with 
allogenic blood and blood product transfusions (5,16).  One antifibrinolytic in particular, 
tranexamic acid (TXA), has been well studied for use in scheduled elective orthopedic surgery 
with emphasis on total hip arthroplasty and total knee arthroplasty (1, 6, 8, 11).  TXA is a lysine 
amino acid derivative that prevents break down of the fibrin clot.  TXA competitively binds to 
plasminogen.  This competitive binding action obstructs naturally occurring lysine from binding 
with plasminogen thus preventing the formation of the enzyme plasmin.  Inhibition of the 
conversion of plasminogen to plasmin preserves the formed fibrin clot thereby decreasing blood 
loss at the site of bleeding or injury via clot stabilization (2, 8, 9,).  
 
CRASH-2 (27) is one of the largest studies to date conducted for the purpose of examining the 
effects of TXA administration.  CRASH-2 assessed the use of TXA in trauma patients with the 
goal of reducing death rates due to uncontrolled bleeding.  Results from CRASH-2 showed a 
significant decrease in bleeding following trauma and ultimately determined that the 
administration of TXA to trauma patients yielded a decrease in the observed death rate (27).  
Due to the promising results observed in the CRASH-2 study, The World Health Organization 
(WHO) was prompted to add TXA to its list of essential medications for trauma and those at 
significant risk of ongoing hemorrhage (2, 10).  
 
Currently, the FDA approved on-label indications of TXA are use in the short-term treatment of 
hemophilia patients undergoing dental extractions and in the management of patients 
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experiencing menorrhagia (10).  Despite the current limited scope of FDA approval for TXA, 
antifibrinolytic therapy use during elective surgery in otherwise clotting-uncompromised patients 
is not a new concept.  TXA has been administered in cardiopulmonary bypass, ENT, orthopedic, 
spinal fusions, and hysterectomies as an aid to decrease blood loss.  Numerous studies have 
examined the efficacy, and safety, of TXA use for the reduction of intraoperative blood loss in 
orthopedic surgeries specifically, total knee and total hip arthroplasty (21).  In reports examining 
lower total joint replacement surgeries, TXA reduced intraoperative blood loss, rate of allogenic 
blood transfusions, and total length of hospital stay (18,19,20,22).  All of these individual results 
appear to work synergistically and ultimately resulted in a reduction in the overall cost of the 
procedure and decreased costs relayed to the patients (8, 11,16). Limited research exists 
examining the efficacy of TXA administration in the perioperative period for the traumatic hip 
fracture population.  Based on the entire body of prior research conducted to date, it is reasonable 
to hypothesize that administration of TXA in these traumatic instances would also yield a 
decreased blood loss and therefore could possibly contribute to lower rates of allogenic blood 
transfusion in the traumatic hip fracture population.  
 
Each year over 300,000 hip fractures occur in the United States.  This number is projected to 
increase to over 500,000 by the year 2040 (23, 25). In the >65-year-old population, one-year 
mortality rate associated with hip fracture is between 12% to 36% in the 65 and older population 
and the 5-year mortality rate reaches upwards of 60% (24, 25).  Factors affecting mortality 
include pre-existing comorbid conditions, preoperative health status, pre-fracture mobility, age, 
and sex (9).  With blood loss beginning at the moment of injury and continuing through out the 
postoperative recovery period, typical patients may experience an average perioperative blood 
loss in upwards of 1500 mLs (28,12).  Significant blood loss in an already vulnerable elderly 
population has the potential to dramatically increase the need for allogenic blood transfusions.  
Allogenic blood transfusions have been linked to an increase in postoperative infection rates and 
prolonged hospital stays (3,11).  Patients that receive allogenic blood transfusions are twice as 
likely to develop an infection when compared to non-transfused patient cohorts (3).  
 
Cardiac disease and renal disease are common comorbid conditions exhibited by a majority of 
the elderly hip fracture patient population (9).   Patients with significant cardiac disease have an 
increased incidence of poor outcomes in the presence of large volume blood loss.  Patients with 
pre-existing renal compromise are at risk for pulmonary complications associated with volume 
loading during receipt of allogenic blood transfusion.  Reduction of allogenic blood transfusions 
in both the renal and cardiac compromised hip fracture population has the potential to 
significantly decrease the risk of known adverse events frequently seen in patients with these 
pre-existing comorbid conditions.   
 
Lee et al (29) examined the efficacy of TXA administration in patients receiving hip 
hemiarthroplasty surgery following a hip fracture.  Transfusion rates within the TXA group were 
reported at 6% and for those in the placebo group at 19%.  Zuffrey et al (7) explored the use of 
antifibrinolytics in orthopedic surgery to reduce allogenic blood transfusions.  Three 
antifibrinolytic were used in this study:  aprotinin, amicar and TXA. For the purpose of this study 
only results pertinent to TXA will be discussed.  Primary surgeries investigated included total 
knee arthroplasty and total hip arthropalasty.  Allogenic blood transfusion rates and the total 
perioperative blood loss were significantly (P<0.01) decreased when TXA was administered.  
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Zuffrey et al (7) also examined complications in the setting of antifibrinolytic administration.  
The rate of venous thromboembolism in the TXA group (20.9%) was no different when 
compared to the control group (20.8%).   
 
In a second study by Zufferey et al (15) the use of TXA in hip fracture surgery was studied.  One 
hundred and ten patients participated in the study.  Patients received one dose of TXA prior to 
incision and a second dose 3 hours later.   The rate of allogenic blood transfusion was 42% in the 
TXA group as compared to 60% in the control group.   A slightly increased incidence of adverse 
vascular events reported in this study was not statistically significant (15).   
 
Poren et al (13) investigated the safety of TXA use in 872,416 patients undergoing total hip 
arthroplasty and total knee arthroplasty.  The primary outcome of this study was TXA use to 
decrease allogenic blood transfusions while not increasing the risk for thromboembolic 
complications.  Patients that received TXA exhibited an allogenic transfusion rate of 7.7% while 
the control group had at 20.1% transfusion rate.  Thromboembolic complications occurred at a 
rate 0.6% in the TXA group as compared to 0.8% in the control group.  Poren et al demonstrated 
the ability of TXA to decrease the requirement of allogenic blood transfusions while not 
significantly increasing adverse vascular outcomes.  
 
Das et al (14) focused their study solely on the use of TXA in patients undergoing hip fracture 
surgery.  Patients were either an ASA (American Society of Anesthesiologist) physical 
classification status I or II between the ages of 18-80.  Of the 90 participants in this study, 45 
were randomized into the test group and received TXA while 45 were randomized into the 
control group and did not receive TXA.  Primary outcomes for this study included examination 
of the volume of blood in the patients surgical site drain postoperatively, percentage of 
hemoglobin fall on postoperative day 0 and day 2, and allogenic blood transfusion rates.  The 
blood volume output into the surgical site drains for the TXA group was 39.33+/-10.09ml 
compared to 91.11+/-17.61 in the control group.  Hemoglobin drop in the TXA on day 0 was 
2.99+/-3.45 compared to the control group of 7.70+/-6.05.  On postoperative day 2, TXA 
hemoglobin drop was 0.35+/-0.74 and the control group was 2.72+/-2.7.  Eighteen of the 45 
patients in the control group received an allogenic blood transfusion while only 7 out of 45 
patients in the TXA group required transfusion.   
 
A 2011 Cochran Review (30) examined the effect of using TXA vs. placebo on the rate of 
allogenic blood transfusion and adverse vascular events.  A total of 4,842 patients were 
randomized into either the TXA group or the control group receiving a placebo.  The population 
receiving TXA realized a reduction in the rate of allogenic blood product transfusion of 39%. 
Furthermore, the risk of adverse vascular events such as myocardial infarction, stroke, deep vein 
thrombosis, pulmonary embolism, or development of renal disease or dysfunction did not 
increase when TXA was administered.  Also, the use of TXA was not associated with an increase 
in risk for mortality (30).   
 
Literature review has shown that limited evidence exists looking at the efficacy of TXA use for 
decreasing allogenic blood transfusion in hip fracture patients.  This study aims to provide high 
quality evidence to support the use of TXA in the traumatic hip fracture population.  Use of a 
single dose of TXA is expected to improve overall patient outcome through the reduction of 
TRANEXAMIC ACID AND HIP FRACTURES  
 
37 
blood loss while concomitantly maintaining a low level of vascular sequale that may be 
attributed to the use of an antifibrinolytic therapy in the setting of trauma. 
 
Numerous studies support the use of TXA in elective joint replacement surgery to decrease 
perioperative blood loss, decrease blood transfusion rates, decrease length of hospital stay, and 
decrease cost to the patient. Patients undergoing elective orthopedic surgery have been medically 
optimized to achieve the most successful outcomes.  Patients who have sustained a traumatic hip 
fracture may not be optimized and are therefore more likely to be considered fragile given their 
age, trauma status, preoperative baseline health, and presence of perioperative blood loss.  When 
considering these factors, decreasing blood loss during the perioperative period and reducing the 
need for allogenic transfusion is likely to realize improved postoperative outcomes in this patient 
population. 
 
Objectives: 
 
Primary Objective:  Determine if the use of TXA reduces perioperative blood loss and 
therefore reduces the need for allogenic blood transfusion in patients undergoing surgery to 
repair hip fracture. 
 
Secondary Objectives:  Determine if the reduction in allogenic blood transfusion imparts a 
concomitant reduction in the incidence of complications such as infection, LOS, and death.  
Determine if use of TXA in this patient population imparts an increased risk of adverse vascular 
events and death.  
 
Study design/methodology: 
This is a prospective, randomized, double-blinded, off label trial.  Any patient at or over the age 
of 65 presenting to CMMC for the ORIF repair of a traumatic hip fracture may be considered for 
inclusion in this study.   
 
Patients may be enrolled into the study by one of the study’s Clinical Research Coordinators.  
The Clinical Research Coordinators able to obtain informed consent are the M2 Clinical 
Coordinators Jay Bachelder, Robyn Begin, Carie Whitmore, or Maija Comeau.  When patients 
enter the facility with a hip fracture via the Emergency Department, the RN House Supervisor 
will alert the M2 Clinical Coordinator to their arrival.  This will trigger the Clinical Coordinator 
to review the patient’s history and physical, demographics, and nature of their injury.  Should the 
patient meet the inclusion criteria outlined below, the Clinical Research Coordinator may 
approach the patient to consent them for enrollment into the study.  Informed Consent will be 
obtained by reading the Informed Consent literature to the patient and answering any questions 
that may arise.  The Clinical Research Coordinator will then personally deliever the consent to 
the pharmacy where the consent will be secured in a locked filing cabinet.   
 
Study Population: 
Inclusion/Exclusion Criteria: 
Inclusion Criteria: Any patient over the age of 50 presenting to Central Maine Medical 
Center with hip fracture that consents to participate in the study may be included in the study. 
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Exclusion Criteria: Patients who are anticoagulated or have a history of vascular events 
such as stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis or a clotting 
disorder. Patients with unknown medical histories or if a full medical history can not be obtained 
they will be excluded from the study.   
 
 
Study Drug/Interventions: 
Study participants will be randomly assigned to either the placebo group or the intervention 
group.  Participants in the placebo group will be administered 100mL of normal saline 15 
minutes prior to skin incision.  Participants in the intervention group will be administered 
1,000mg tranexamic acid reconstituted into 100mL of normal saline 15 minutes prior to skin 
incision.   
 
Sarah Green, PharmD will be unblinded in this study.  She will produce randomized kits in the 
CMMC Inpatient Pharmacy numbered from 1 to 125.  Randomized TXA and placebo kits will be 
created in batches of 20.  ½ of the kits will contain TXA and ½ will contain placebo.  As patients 
are added to the study, the Inpatient Pharmacy will dispense the kits based on the patient’s 
number of entry into the study.  When a patient is enrolled into the study by one of the Clinical 
Research Coordinators, they will be sequentially added to the study list and tracked by FIN 
number within the Inpatient Pharmacy by Sarah Green.  No personal identifier will be used in the 
randomization.   
 
Study Schedule: 
The study will take place starting 01/11/2017 to 01/11/2018 
 
Adverse Event Reporting: 
Adverse events are entered into the MIDAS system at CMMC.  Either the RN or provider 
responsible for direct patient care may make entries into the MIDAS system.  All adverse events 
related to orthopedic patients involved in this study will be reported to Elizabeth Tourcotte.   
 
Statistical Analysis Plan: 
N=125  
Defer to statistician. 
 
Informed Consent Process: 
 
Privacy and confidentiality 
Privacy and confidentiality will be maintained pursuant to hospital policy and standards. 
 
Patients or their healthcare decision makers will be verbally consented by their surgeon prior to 
enrollment in the study.  Signed consent forms will be obtained as verification.  Additionally, an 
informational handout detailing the study objectives as well as potential risks and benefits to 
participation will be provided to patients at the time of consent.     
 
Risk/Benefit: 
Risk to participants: 
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Adverse vascular event including, but not limited to, myocardial infarction, symptomatic DVT, 
pulmonary embolism are possible.  Zuffery et al (15) reported the probability of vascular events 
at 6 weeks post recipt of TXA was 16% vs. 6% in their placebo group while a larger study 
conducted by Das et al (14) reported no thromboembolic episodes.  It was suggested that TXA 
will not affect the risk of DVT due to its mechanism of action whereby TXA inhibits fibrinolysis 
in the wound but not in circulation.  
   
Medications that have been shown to have an interaction with IV TXA: 
• Anti-inhibitor Coagulant Complex (Examples: Autoplex T, Feiba NF, Feiba VH 
Immuno): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor 
Coagulant Complex. Combination should be avoided 
• Contraceptives-Estrogens and Progestin (Examples: Yaz, Desogen, brevicon) May 
enhance the thrombogenic effect of Tranexamic Acid. R 
• Fibrinogen Concentrate (Examples: haemocomplettan, fibrinogene T1 and Clottagen): 
Antifibrinolytic Agents may enhance the adverse/toxic effect of antifibrinolytic agenst.  
Specifically, the risk for thrombosis may be increased.  
• Tretinoin (Examples: Avita, Renova, Retin-a): May enhance the thrombogenic effect of 
Antifibrinolytic Agents.  
 
Benefits to participants: 
Reduction in blood loss after experiencing a traumatic hip fracture.  The additional benefits 
stemming from a reduction in blood loss are the reduction in the need to receive blood products.  
Allogenic blood product transfusion carries with it some level of risk which is outlined in other 
areas of this research proposal in more detail. 
 
Study Timeline: 
1 year 
 
Data Safety Monitoring:  
CMMC currently utilizes the MIDAS system for reporting and follow-up on any adverse patient 
events.  Elizabeth Turcotte will be notified directly through the MIDAS reporting system of any 
adverse event occurrence as described above.  Elizabeth Turcotte will present any adverse events 
reported during monthly data reporting meetings with the group at large. Informed consent is 
only for use in enrolling patients into the TXA study and not used as a consent for surgical 
intervention.  The TXA study consents will be secured in pharmacy in a filing cabinet that is 
locked at all times, it is not to become part of the patients’ chart. 
The coordinators will take the consents and bring to the pharmacy to then be secured. 
 
Conflict of Interest: 
None 
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Appendix B 
 
Central Maine Healthcare Corporation 
INSTITUTIONAL REVIEW BOARD 
Central Maine Medical Center 
Bridgton Hospital 
Rumford Hospital 
Deborah Taylor, Ph.D., IRB Chair        Lois N. Downs, IRB  
Jenae Limoges, MD, IRB Vice-chair      Risk Management 
Phone:  (207) 795-8246          300 Main Street                                              
Fax:  (207) 344-0373                        Lewiston, Maine  04240 
 
                                   
 
APPLICATION (FULL BOARD) 
 
Protocol Title:  
 
 
Utilizing Tranexamic Acid to Reduce Blood 
Transfusion in Hip Fractures 
Principal Investigator:   
Morgan Guerrette SRNA 
 
Application for Human Subject Research 
Applications for human subject research will need to meet all outlined requirements listed for each type of 
review in order for a project to be reviewed.  If you have any questions regarding how to complete the 
forms or need help locating a form, please call our office at 207-795-8246. 
Authority of the IRB and IRB Review 
The IRB determines if a project meets the federal definition of research:  “a systematic investigation 
including research development, testing and evaluation, designed to develop or contribute to generalizable 
knowledge.”  The IRB defines a human subject as: “a living individual about whom an investigator 
conducting research obtains: 1) data through intervention or interaction with the individual, or 2) 
identifiable private information.”  This determination is made with the aid of the OHRP guidance 
document: Human Subject Regulations Decision Charts, dated September 24, 2004. 
 
Types of IRB Review 
There are three levels of IRB Review (full board, expedited and exempt), determined by the nature of the 
project, level of potential risk to human subjects and the subject population.   
 
Exempt and expedited review can be given to studies that constitute no more than 
minimal risk to the human subjects, i.e., the risk one experiences in daily living.  These 
reviews are done in the IRB office on a continual basis.   
Full board review is required for studies that involve greater than minimal risk or 
vulnerable populations that require special protections by the IRB.  These require 
review by the convened IRB. 
 
Research Proposals Involving the Use of Protected Health Information (PHI) 
 
How Can Covered Entities Use and Disclose Protected Health Information for Research and 
Comply with the Privacy Rule? 
 
Key Points:  
 
• De-identified health information, as described in the Privacy Rule, is not PHI, and thus is not 
protected by the Privacy Rule. (See List of Identifiers ) 
 
• PHI may be used and disclosed for research with an individual's written permission in the form of 
an Authorization.  
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• PHI may be used and disclosed for research without an Authorization in limited circumstances: 
Under a waiver of the Authorization requirement, as a limited data set with a data use agreement, 
preparatory to research, and for research on decedents' information.  
 
Submission and Review Procedure for Full Board Review 
 
The IRB will provide written notification of the IRB’s determination within ten (10) business days.  This 
notification will be sent via email.  There is requirement for notification of revisions to the IRB for full 
board approvals for changes that may impact the risk/classification of the project.  The IRB does require 
notification of unanticipated events or continuing review of a research that is determined full board. 
 
 
(continued)  
APPLICATION (FULL BOARD) 
 
Title of Protocol:  
 
 
Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures 
Principal Investigator (PI): Morgan Guerrette, 
SRNA 
 
(Person personally responsible for the conduct of 
the research) 
 
Dept/Address:  CMMC 
Anesthesia Department 
300 Main Street 
Lewiston ME 04240 
 
Phone: 207-795-
2669 
 
Co-Principal-Investigator (co-PI): Katherine 
Balzano-Cowan, SRNA 
 
(Person equally responsible for the conduct of the 
research) 
 
Dept/Address:  CMMC 
Anesthesia Department 
300 Main Street 
Lewiston ME 04240 
Phone: 207-795-
2669 
 
Sub-Investigator: Tina Moring, Sarah Green, 
James Osgood, Elizabeth Turcotte 
 
(Person who is a member of the research team 
designated and supervised by the investigator to 
perform study-related procedures and/or to make 
important study-related decisions) 
Dept/Address: CMMC 
Anesthesia Department 
300 Main Street 
Lewiston ME 04240 
 
 
 
Phone: 207-795-
2669 
 
Funding/Protocol Information 
Who wrote the protocol or plan for this study?  
(please choose only one)  
 
Funder/Sponsor (listed below under C)        
Cooperative Group PI:              
 Principal Investigator: (listed above)  
Other:    
 
Is this protocol being supported by a federal funding 
agency or non-funded 
e.g. NIH, AHA, etc.?    
Yes    No  
 
If yes, please provide a copy of the entire Grant 
(research plan) for review. 
 
What funding agency is supporting your protocol:   
 
Grant Title:   
 
 Is this protocol being sponsored by an Industry 
(Pharmaceutical or Device) Sponsor? 
 
Yes    No  
 
 
 
(Please list the company below, even if you are not receiving monetary support.) 
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(continued)  
APPLICATION (FULL BOARD) 
 
 
 
Name of Industry Funder/Sponsor:   
 
 
 
Contact Person & Title:   
 
 
Address:   
 
 
Address:   
 
 
Phone:                   
                      
 
 Fax:   
 
 
 
If this protocol is not being funded by either a funding 
agency, or an industry sponsor, please indicate where 
the funding for the conduct of this protocol is being 
obtained (if any): 
Non-Funded   
Departmental Funding   
Cooperative Group 
 
 
 
Location of Research 
 
Where will the study take place?   
 
Central Maine Medical Center 
Will the PI be conducting and/or supervising study 
related activity at any sites not under the jurisdiction of 
this IRB/Privacy Board?                                    
Yes    No  
    
If yes, please attach to this application and provide name 
and address for each location AND documentation of 
approval to conduct the research at these sites. 
 
 
Note: CMHC IRB approval of your protocol does not include permission to perform any protocol-related 
activities at these sites.  Additional IRB approval may be required from these sites. 
 
 
 
 
(continued)  
APPLICATION (FULL BOARD) 
 
Will this study require hospital admission?                                    Yes    No  
 
If yes, you must notify the Admissions Department at 
755-3892 after IRB approval. 
 
Do you have attending privileges at CMHC (CMMC, 
Rumford Hospital, Bridgton Hospital)?   
Yes    No  
 
Are you an employee of CMHC (CMMC, Rumford Yes    No  
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Hospital, Bridgton Hospital)?  
 
 
 
If no, to both question you must have a CMHC sponsor. 
 
 
Please provide the name of that person:  
 
 
Tina Moring 
 
Subject Information 
 
Subjects will be:   (check all that apply) 
 
Inpatients       Outpatients          
Non-Patients  Males          Females 
 
Will subjects who do not understand English be enrolled? Yes    No  
 
If yes, describe your resources to communicate with 
these subjects:  Indemand interpreting services  
Potentially Vulnerable Populations:   
 
Children   Prisoners     None   
Students   Pregnant Women 
 
Other(describe):   
 
 
Recruitment 
 
How many subjects does your site anticipate recruiting?   
 
125 
Who will be approaching potential subjects for informed 
consent?   
Dr. David Brown MD 
Dr. Jeffrey Bush MD 
Dr. Matthew Bush MD 
Dr. Paul Cain MD 
Dr. Patrick Fallon MD 
Dr. Michael Regan MD 
Dr. James Timoney Do 
 
(continued)  
APPLICATION (FULL BOARD) 
 
How much time will subjects have to make a decision 
about study participation? 
15 min 
Potentially Vulnerable Populations:   
 
By chart /database review                              
Course participants 
From the Investigator’s own patients           
Living conditions (street, nursing home) 
Referrals                                           
Circumstance (i.e.hospital admission, homeless) 
Describe any other sources:   
Direct Advertising  
List here:  
 
How will subjects be identified as potential research 
subjects? 
 
When CMO is consulted for ORIF of hip fracture in 
the emergency room 
How will subjects be recruited for participation? 
 
At a scheduled visit by the investigator 
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Letter (Please attach letter to this application) 
Phone 
Other (describe): when patient is consented for 
surgery 
By chart / database review  
 
Who is the custodian of the above indicated chart(s) / 
database(s) used for recruitment?   
 
surgeons 
Describe how the custodian is going to contact the 
subject(s).   
 
Via consent/flagged in the ED prior to surgery 
 
Initial contact to potential subjects must be made by the custodian of the chart(s)/database(s). 
Please attach any letters, ads or other information that will be sent to the subjects. 
 
Direct advertising for subject recruitment includes: 
 
Radio                                  Television                                 Letters to patients 
Newspaper               Bulletin board / flyer              None               
Internet                               Other                                          
 (continued)  
APPLICATION (FULL BOARD) 
 
 
Payment to Subjects 
 
Will subjects be paid for participation?                                               
 
Yes    No  
 
If yes, indicate total amount, (dollar or equivalent):  
 
 
 
Form of Payment:   
(Payment includes all types of reimbursement such as 
fares, parking fees, etc.) 
 
 
Explain how payments will be made and if the payments 
are prorated please explain why?   
 
Are there any services that will be provided without 
charge? 
Yes    No  
 
Explain these services if answer is yes:   
 
  
 
Type of Research 
 
Are there any services that will be provided without 
charge? 
Yes    No  
 
If yes, name of radioactive drug(s):   
 
Does study involve the administration of radioactive 
drug(s)? 
Yes    No 
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Does study involve additional x-ray procedure(s)?                            Yes No  
 
If yes, name of procedure(s):  
 
 
Number of procedures:   
 
Does study involve psychological tests?                                              Yes    No  
 
If yes, tests to be used:   
 
(continued)  
APPLICATION (FULL BOARD) 
 
 
Type of Research 
Does the study involved the use of questionnaires? Yes    No  
 
If yes, provide copies of the questionnaires.  
 
Does study involve the use of discarded human 
tissue/fluids?                  
Yes    No  
 
 
Does study involve the use of fetal and abortus tissues?                           Yes    No  
 
 
Does study involve surgical procedures? Yes    No  
 
If yes, procedures to be used:   
ORIF of hip fracture 
Does study involve dental procedures? Yes    No  
 
If yes, procedures to be used:   
 
Does study involve videotaping/audiotaping or use of 
photographs 
Yes    No  
 
 
 
Does study involve blood draws?                                                               Yes    No  
 
 Separate draw for research purposes, or   
 Additional draw during diagnostic testing 
 
Amount per draw: ml         # of draws:  
 
Does the study involve any procedures/tests that are not 
included above? 
Yes    No  
 
If yes, include a list of these procedures/tests: 
 
 
Is this study already open nationally?                                             Yes    No  
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If yes, include all updates and Data Safety Monitoring 
Board (DSMB) reports.   Past individual Adverse 
Event Reports are not necessary.   
 
(continued)  
APPLICATION (FULL BOARD) 
 
 
Does this Project Involve Investigational Drugs/Devises (IND/IDE) Yes    No 
 
 
If yes complete this section and submit an Investigational Drug or Device Data Form. 
This study involves a  
drug or biologic:  
 
Yes    No  
 
IND#:  
 
 
 
Name of Drug or biologic:  
 
 
Sponsor of Drug or 
biologic:   
 
This study 
is: 
Phase 1      Phase 2     Phase 
3           
Phase 4          Treatment 
 
This study involves a 
device:  
 
Yes    No  
 
IDE#:   
 
Sponsor of Drug or biologic:  
 
 
Sponsor of Drug or 
biologic:   
 
This device 
is:    Investigational    
Humanitarian 
exemption Marketed Significant 
Risk Device                  
Non-
Significant Risk 
Device* 
 
 
*Sponsor must include justification on Non-Significant Risk per 21 CFR 812.66 
 
Please Provide Brief Synopsis of Protocol below: 
 
Summary of Protocol is Attached 
 
The undersigned accepts responsibility for assuring that with regard to this protocol, all applicable FDA 
and HHS regulations and Institutional Policies relative to the protection of the rights and welfare of 
human research participants are adhered to. 
 
 Morgan Guerrette        October 14, 
2016   
Signature        Date 
 
 
  Morgan Guerrette     Principle Investigator  
Print Name        Title 
 
The undersigned acknowledges a review and examination of this research proposal has been completed 
and assures that this study is appropriate to be conducted at CMHC and that all funding, staffing and 
budgetary concerns will be approved before enrollment begins.  This authorization is required before the 
Principal Investigator can submit this project to the IRB for review. 
 
_________________________________________                 ______________________________ 
Signature of Chair/Vice-Chair       Date 
(continued)  
APPLICATION (FULL BOARD) 
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*HIPAA waiver criteria (check all that apply) 
 
If “PHI” being used?  ….  
(see list of identifiers attached)   
 
Is HIPAA Authorization language required?  
 
 Yes (If “Yes” please include HIPAA authorization 
language in the informed consent)   
 
 No(Can only be “No” if *Informed Consent waiver 
and *HIPAA waiver criteria are met) 
 
The use or disclosure of protected health information involves no more than minimal risk to the privacy 
of individuals, based on at least the presence of all the following elements: 
 
Is a Limited Data Set (see below list) being 
used? 
 Yes  No 
 
(If “Yes”, provide a copy of the executed Data Use 
Agreement. 
 
 Data Use Agreement - An agreement into which the covered entity enters with the intended recipient of 
a limited data set that establishes the ways in which the information in the limited data set may be used 
and how it will be protected 
 
 
Limited Data Set with Data Use Agreement 
A data set that excludes the following direct identifiers can be considered a Limited Data 
Names  
Postal address info (if other than city, town, state, 
and ZIP)  
Telephone and fax #s  
E-mail address  
Social Security #  
Medical record numbers  
Health plan #s  
Account #s 
Certificate/license #s  
VIN and Serial #s, license plate #s  
Device identifiers, serial #s  
Web URLs  
IP address #s  
Biometric identifiers (finger prints)  
Full face photographic images and any comparable 
images 
The Limited Data Set CAN contain: 
 
Elements of Dates i.e. Admission, Discharge, Service and Death Dates 
City, Town, State and Zip Code(s) 
Other unique identifiers, characteristics and codes not previously listed as direct identifiers 
 
 
 There is an adequate plan to protect the identifiers from improper use and disclosure.  An adequate 
plan to destroy the identifiers at the earliest opportunity consistent with conduct of research, unless 
there is a health or research justification for retaining the identifiers or such retention is otherwise 
required by law. 
Describe your plan:  
 
 
 
(continued)  
APPLICATION (FULL BOARD) 
 
 
and 
 
 Adequate written assurance that the protected health information will not be reused or disclosed to 
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any other person or entity, except as required by law, for authorized oversight of the research study, 
or for other research for which the use and disclosure of protected health information would be 
permitted by this subpart. 
Describe your plan: 
 
 
 
   
or 
    
 The research could not practicably by conducted without the HIPAA waiver or alteration. 
Provide explanation:  
 
 
or 
 
 The research could not practicably by conducted without access to and use of the protected health 
information. 
Provide explanation:  
 
 
 
 
List of Identifiers Related to PHI 
 
Names 
Geographic subdivisions smaller than a state 
Zip Codes 
Dates (birth, admission, discharge, death) 
Age, if over 90 
Telephone numbers 
Fax numbers 
E-mail addresses 
Social Security numbers 
Medical Record numbers 
 
Health plan beneficiary numbers 
Account numbers 
Certificate and license numbers 
Vehicle identification and serial numbers 
License plate numbers 
Device identifiers and serial numbers 
URLs 
Internet Protocol address numbers 
Biometric identifiers (finger and voice prints) 
Full face photos and comparable images 
Any other unique identifiers 
If PHI is being used and not part of a Limited 
Data Set is the data going outside of CMHC? 
 Yes  No 
 
 (If  “Yes”, please provide a copy of an executed Business Associate 
Agreement. 
 
 
 
 
(continued)  
APPLICATION (FULL BOARD) 
 
Identify Activities Preparatory to Research 
For activities involved in preparing for research, covered entities may use or disclose PHI to a researcher 
without an individual's Authorization, a waiver or an alteration of Authorization, or a Data Use 
Agreement.  However, the covered entity must obtain from a researcher representations that (1) the use or 
disclosure is requested solely to review PHI as necessary to prepare a research protocol or for similar 
purposes preparatory to research, (2) the PHI will not be removed from the covered entity in the course of 
review, and (3) the PHI for which use or access is requested is necessary for the research. The covered 
entity may permit the researcher to make these representations in written or oral form.  
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Please describe this use and disclosure of PHI: 
 
 
 
According to HHS guidance on the Privacy Rule, the preparatory to research provision permits covered 
entities to use or disclose protected health information for purposes preparatory to research, such as to aid 
study recruitment. However, the provision at 45 CFR 164.512(i)(1)(ii) does not permit the researcher to 
remove protected health information from the covered entity's site. As such, a researcher who is an 
employee or a member of the covered entity's workforce could use protected health information to contact 
prospective research subjects [emphasis added]. The preparatory research provision would allow such a 
researcher to identify prospective research participants for purposes of seeking their authorization to use 
or disclose protected health information for a research study. 
 
 Yes, I agree to the above. 
 
             
  
Signature        Date 
 
 
             
  
Print Name        Title 
 
 
 
 
 
continued)  
APPLICATION (FULL BOARD) 
 
FOR IRB USE ONLY 
Is an Informed Consent Required?  
 Yes  No (Research meets all four CFR *ICF waiver criteria listed below) 
 
Informed consent waiver criteria (check all that apply) 
 
 The research involves no more than minimal risk to the subjects, 
 The waiver or alteration will not adversely affect the rights and welfare of the subjects, 
 The research could not practicably be carried out without the waiver or alteration, and 
 Whenever appropriate, the subjects will be provided with additional pertinent information after 
participation. 
 
 
DETERMINATION 
 
 Informed Consent and HIPAA waiver criteria are met and Waiver of Authorization was approved  
 
 
IRB Recommendation:  
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 This project is approved 
 This project is not approved; further details provided within IRB’s determination letter. 
 
Certification:  I have reviewed the above-captioned protocol for general scientific & medical validity 
and safety. 
 
             
  
Signature        Date 
 
 
             
  
Print Name         Title 
 
 
 
 
 
 
 
 
 
 
(continued)  
APPLICATION (FULL BOARD) 
 
IRB REVIEW FEE POLICY 
 
It is a standard practice among Institutional Review Boards to charge a fee to commercial sponsors for 
new studies reviewed by the full Board, new studies that can be reviewed as expedited and studies that are 
up for a continuing review.   
 
Effective January 2010, the IRB fees are as follows: 
 
• $2,000.00 fee (increased from $1,750.00) for new studies reviewed by the full Board,  
• $500.00 fee (no fee increase) for new expedited studies reviewed (protocols reviewed by a 
single IRB reviewer), 
• $250.00 fee (new fee) for all continuing reviews or amendments whether full Board or 
Expedited.  
 
These fees do not currently apply to non-funded, or federally-funded research.  IRB initial review 
applications will request sponsor billing information for the billing of these fees with an expectation that 
the Study Coordinators/Principal Investigators will notify the IRB of any address changes for billing.  The 
IRB Administrator will forward a copy of the billing information to the Director of Research who will 
process the bill with the sponsor.  Once CMHC receives the IRB fee either the Director of Research or 
Accounts Payable office will notify the IRB Administrator payment has been received.  This fee is for 
IRB review and is not contingent upon approval.   
 
Upon notice by the Principal Investigator the IRB may waive this fee if the IRB finds the fee would create 
a meaningful obstacle to research conduct. 
 
 
Billing Contact Person Name:  
 
 
 
Phone:   
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Sponsor Name: 
 
 
 
Sponsor Mailing Address:  
 
 
 
 
For office Use: 
IRB#:                   
 
 Full Board: ($2,000.00)         
 Expedited: ($500)  
Protocol Entitled [as given above]:  
 
Account No:   
 
Billing Information:   
 
Fee for IRB processing of Principal Investigator:   
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Appendix C 
Support Material  
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October 16, 2016 
 
Dear Institutional Review Board Committee Members,  
 
This letter is to inform you that no conflict of interest exists between Kate Balzano-Cowan and Morgan 
Guerrette regarding our involvement with the project: Utilizing Tranexamic Acid to Reduce Blood Transfusion in 
Hip Fractures.  No promises of profit or advantage were made from Central Maine Medical Center for the work 
provided to this project.  Additionally, participation in this project does not guarantee a positive outcome or passing 
grade from the University of New England concerning our Senior Capstone Project or other classroom work.  
 
 
Sincerely,  
 
Morgan Guerrette and Kate Balzano-Cowan 
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TRANEXAMIC	  ACID	  PATIENT	  INFORMATION	  
	  
	  
	  
WHAT	  IS	  TRANEXAMIC	  ACID?	  
Tranexamic	  acid	  (TXA)	  is	  given	  through	  an	  IV	  to	  prevent	  or	  reduce	  bleeding	  and	  reduce	  the	  
need	  for	  blood	  transfusions	  during	  a	  trauma	  or	  surgery.	  	  	  
	  
WHY	  IS	  THIS	  STUDY	  BEING	  DONE?	  
This	   research	   is	   being	   done	   because	   we	   have	   seen	   excellent	   results	   using	   tranexamic	   acid	  
during	   scheduled	   hip	   and	   knee	   replacements.	   	   Research	   has	   shown	   patients	   receiving	  
tranexamic	  acid	  before	  scheduled	  surgery	  to	  replace	  hip	  and	  knee	  joints	  bleed	  less.	   	  We	  hope	  
that	  using	  this	  drug	  in	  traumatic	  hip	  fractures	  will	  give	  patients	  the	  same	  benefit.	  
	  
ARE	  THERE	  BENEFITS	  TO	  TRANEXAMIC	  ACID?	  
Tranexamic	  acid	  has	  been	  shown	  in	  other	  research	  to	  reduce	  bleeding	  and	  the	  need	  to	  be	  given	  
blood	   from	   another	   person	   after	   traumatic	   accidents	   and	   before	   planned	   hip	   and	   knee	  
replacement	  surgeries.	  
	  
ARE	  THERE	  RISKS	  AND	  SIDE	  EFFECTS	  OF	  TRANEXAMIC	  ACID?	  
Risks	  and	  side	  effects	  related	  to	  giving	  tranexamic	  acid	  to	  reduce	  blood	  loss	  might	  include:	  
Adverse	  vascular	  event	  including,	  but	  are	  not	  limited	  to,	  myocardial	  infarction	  (very	  rare	  but	  
serious),	  symptomatic	  DVT	  (less	  likely	  but	  serious),	  or	  pulmonary	  embolism	  (less	  likely	  but	  
serious).	  
	  
	  
For	  more	  information	  about	  risks	  and	  side	  effects,	  and/or	  to	  report	  side	  effects	  and	  adverse	  
events.	   	   Please	   speak	   to	   the	   researcher	   or	   contact	   Elizabeth	   Turcotte,	   RN	   via	   phone	  
(207.795.2134)	  or	  email	  (TurcotEl@cmhc.org).	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2/2/17
1
TXA Fracture Study
January 2017
CMMC-OICM-CMO-UNE
TXA:  Current Uses
• Total knee replacements
• Total hip replacements
• Literature demonstrates TXA reduces blood product 
utilization 
• Nationally being widely utilized for traumas etc...
• CRASH-2 STUDY
TXA:  Hip Fracture Study
• GOAL: to see a decrease in blood utilization and 
better outcomes for patients with hip fracture
• Starting January 11, 2017 
• Patients with fractured hips can be entered into TXA 
study
• Each patient receives a hospitalist consult
• Based on patient history they can either be included 
in the study or excluded 
Inclusion/Exclusion Criteria
Inclusion Criteria:
• Any patient over age 50 with 
hip fracture
• Gives consent to participate in 
the study
Exclusion Criteria: 
• Anticoagulated
• History of  vascular events:
o stroke 
o myocardial infarction 
o pulmonary embolism 
o deep vein thrombosis 
o clotting disorder 
• Patients with either unknown
or if  a full medical history can 
not be obtained
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2/2/17
2
Process
• Patient receives hospitalist consult at admission
• Determined to be either potential inclusion or ruled 
an exclusion 
• Patient will receive a packet and face to face time to 
complete the informed consent
Consents
• Patients selected as “meets criteria” for inclusion:
• Patient/POA will be educated - literature and 
discussion about what is TXA, risks, benefits
• If  they choose to enroll in the study - consent will be 
obtained 
• “Study drug” will be ordered and patient will receive 
either TXA or placebo
Who orders the drug?
• Ideally the surgeon will order the drug
• The drug is ordered by entering the words “study 
drug”
• If the surgeon is not able to order the drug, the 
Clinical Coordinator or the CRNA will order the 
drug as a verbal order under the surgeon
• The pharmacy will send the “study drug” as an on 
call medication when the patient is going to the OR
Who gets Consents
• Consents can only be obtained by those who are 
listed on the IRB application 
• Surgeons CMO/Clinical Coordinators M2/Jim 
Osgood or Tina Moring/Morgan Guerrette or Kate 
Balzano-Cowan
• Primarily Clinical Coordinators during weekday 
hours
• Jim Osgood or Tina Moring on weekend hours
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2/2/17
3
What do we need to know?
• Starting in 2017 TXA for fractured hips may be given –
“Study Drug”
• It is a one time dose much like TXA for total hips now
• Sign off  on the MAR as “study drug”
• Either TXA or Placebo drug will be administered
• Providers (surgeons, nurse, CRNA) will be blinded as to 
what the patient has received either TXA or placebo
Post Op
• Post op patients will be entered into a data base and 
tracked for blood product utilization and/or 
complications
• Data will be followed for approximately 1 year
• Communicate with PACU/Post op team that patient 
was enrolled in the “study”
• Goals: see a decrease in blood product utilization 
and better outcomes for patients with hip fracture
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Appendix D 
Informed Consent 
Central Maine Healthcare Corporation 
Authorization to Participate in a Research Project  
 
 
STUDY TITLE: Utilizing Tranexamic Acid to Reduce Blood Transfusion in Hip Fractures  
 
IRB NUMBER: 494 
 
CONSENT VERSION DATE: 10.09.2016 
 
HOSPITAL OR INSTITUTION: Central Maine Medical Center 
 
INVESTIGATOR: Morgan Guerrette 
 
SUBJECT’S NAME (printed):           
 
 
You are being asked to volunteer for a research study.  Research studies include only patients who choose 
to take part.  In order to decide whether you should agree to be part of this research study, you should 
understand enough about its risks and benefits to make an informed choice.  This process is known as 
informed consent.  Please take your time to make your decision. If we are unable to obtain a full medical 
history, you will be excluded from this study.   
 
You are being asked to take part in this study because you have sustained a traumatic fracture to one of 
your hip joints. 
 
 
WHY IS THIS STUDY BEING DONE? 
This research is being done because we have seen excellent results using tranexamic acid during 
scheduled hip and knee replacements.  Research has shown patients receiving tranexamic acid before 
scheduled surgery to replace hip and knee joints bleed less.  We hope that using this drug in traumatic hip 
fractures will give patients the same benefit. 
 
HOW MANY PEOPLE WILL TAKE PART IN THE CLINICAL TRIAL? 
Up to 125 people will take part in this study.  Central Maine Medical Center is the only site approved to 
enroll people into this study. 
 
WHAT IS INVOLVED IN THE STUDY? 
If you decide you would like to participate in this study, you will be “randomized” into one of the study 
groups described below.  Randomization means that you are put into a group by chance.  It is like flipping 
a coin.  A computer decides which group you are put in.  Neither you nor the researcher will choose what 
group you will be in.  You will have an equal chance of being placed in any one group.  The groups are:  
The control group or the drug-receiving group.  Patients in the control group will be treated in the same 
way as all patients coming to the hospital with broken hips are presently treated.  Patients in the control 
group will not receive tranexamic acid before having surgery to repair their broken hip.  Patients in the 
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drug-receiving group will be given 1gram of tranexamic acid before having surgery to repair their broken 
hip. 
 
  
 
• Standard procedures and tests that will be done during the trial which are part of the regular care of a 
patient with a hip fracture are complete blood counts done the day of your surgery and at regular intervals 
after surgery as determined by your doctor. 
 
• There are no additional standard procedures or tests that will be done during the trial that are being done 
because of participation in the trial. 
 
 
• Should you be randomized into the drug-receiving group, giving you the tranexamic acid prior to your hip 
surgery is the only procedure/test that is considered experimental and being tested in this trial.  
 
HOW LONG WILL I BE IN THE STUDY? 
We think you will be in the study for the length of your admission to the hospital to have your broken hip 
fixed. 
 
Should you decide to take part in this study, there is no reason the researcher may decide to take you off 
this study. 
 
You can stop participating at any time.  However, if you decide to stop participating in the study, we 
encourage you to talk to the researcher and your regular doctor first.  There are no serious consequences 
of sudden withdrawal from the study and there are no additional testing or procedures that would need to 
be done in order for you to safely withdraw from this study. 
 
WHAT ARE THE RISKS OF THE STUDY? 
While in this study, you are at risk for these side effects listed below.  You should discuss these with the 
researcher and/or your regular doctor.  There also may be other side effects that we cannot predict; in 
some cases side effects can be serious or long lasting or permanent. 
 
Risks and side effects related to giving tranexamic acid to reduce blood loss might include: 
Adverse vascular event including, but are not limited to, myocardial infarction (very rare but serious), 
symptomatic DVT (less likely but serious), or pulmonary embolism (less likely but serious). 
 
For more information about risks and side effects, and/or to report side effects and adverse events speak 
to the researcher or contact Elizabeth Turcotte, RN via phone (207.795.2134) or email 
(TurcotEl@cmhc.org). 
 
ARE THERE BENEFITS TO TAKING PART IN THE CLINICAL TRIAL? 
You may benefit from the being given tranexamic acid prior to your hip surgery provided to you by this 
research.  Tranexamic acid has been shown in other research to reduce bleeding and the need to be given 
blood from another person after traumatic accidents and before planned hip and knee replacement 
surgeries. 
 
WHAT OTHER OPTIONS ARE THERE? 
Instead of being in this study, you have the option to decline and will be treated in the same way as 
patients randomized into the control group of this study.   
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Please talk to your regular doctor about these and other options. 
 
WHAT ABOUT CONFIDENTIALITY? 
Efforts will be made to keep your personal information confidential.  We cannot guarantee absolute 
confidentiality.  Your personal information may be disclosed if required by law.  All of your personal and 
medical data will be handled in the same way all other personal and medical data at Central Maine 
Medical Center is handled.  Your agreement to take part in this study does not mean you agree to have 
your personal information disclosed.  If you choose to withdraw from the study, you may revoke your 
approval for the use of your future medical information.  To do this, you may contact the researcher in 
writing.  Data which has already been collected, will be maintained with the research records. Study 
information collected up to that point will be forwarded to the study sponsor.  No further study 
information will be collected after you withdraw from the study. 
 
WHAT ARE THE COSTS? 
You or your insurance company will not be charged for any tests or services specifically required by this 
research study unless the tests or services are clinically indicated or part of your standard treatment.  You 
will still be responsible for the cost of your usual ongoing medical care, including procedures, non-study 
medications, and tests that your study doctor or regular doctor requires during this study as part of your 
usual medical care. 
 
In the case of injury or illness resulting from this clinical trial, emergency medical treatment is available, 
but will be provided at the usual charge.  Central Maine Medical Center will not compensate you or your 
insurance company in the event of any injury. 
 
Central Maine Medical Center is not being compensated for their participation in this research study by 
the study. 
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Taking part in this study is your choice.  You may choose not to take part or may leave the study at any 
time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled.   
 
We will tell you about new information that may affect your willingness to stay in this study. 
 
PERMISSION TO USE OR RELEASE IDENTIFIABLE HEALTH INFORMATION 
FOR RESEARCH PURPOSES 
 
WHY AM I BEING ASKED TO RELEASE THIS INFORMATION? 
As part of this clinical trial, you are being asked to allow Morgan Guerrette to collect health 
information about yourself.  This information will be collected, entered onto a database with the 
health information from others taking part in this clinical trial, and studied to see if giving 
tranexamic acid before surgery to patients who have broken their hip in a fall lowers their need to 
be given blood products from other people.  Morgan Guerrette may also need to obtain copies of 
any medical records you have with other health care providers. 
 
WHAT AM I BEING ASKED TO RELEASE? 
For this clinical trial, the following information will be collected: 
 Your date of birth  
 Your past medical history 
 Your weight, blood pressure, temperature, lab results, and the results of your physical 
examination during your admission to Central Maine Medical Center to get your broken 
hip fixed. 
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WHO WILL SEE THIS INFORMATION? 
Personnel or members of the Central Maine Medical Center Institutional Review Board or 
personnel from the Office of Human Research Protections may see parts of your medical records 
related to this clinical trial and, therefore, will see your name and other personally identifiable 
information about you.  The information collected is the property of Morgan Guerrette, and you 
will not be able to get it back.   
 
WILL THE INFORMATION COLLECTED AS PART OF THIS STUDY BE DESTROYED WHEN IT IS NO LONGER NEEDED? 
In the event of any publication regarding this study, your identity will not be disclosed.  It is 
difficult for Morgan Guerrette to know how long your information will be kept at least until the 
end of the clinical trial, but most likely it will be kept on a database within the Anesthesia 
Department at Central Maine Medical Center for an indefinite length of time.  We do not know 
when your information will no longer be used, and there is not expiration date after which it will 
be discarded. 
 
 
CAN I STOP MY INFORMATION FROM BEING USED? 
If you choose to withdraw from the study, you may revoke your approval for the use of your future 
medical information.  To do this, you may contact the researcher in writing.  Data that has already been 
collected will be maintained with the research records. Study information collected up to that point would 
be forwarded to the study sponsor.  No further study information will be collected after you withdraw 
from the study. 
 
During the study, you may not have access to your information through the researcher but you may 
request information after research is completed.  All information collected as part of this study will be 
part of your medical record at Central Maine Medical Center.  Should you wish to obtain your 
information through the hospital please contact Medical Records Department and follow their 
instructions. 
 
WHAT IF I DO NOT AUTHORIZE YOU TO COLLECT AND RELEASE MY HEALTH INFORMATION? 
If you agree to be in this clinical trial, you are authorizing the release of your health information as part of 
the trial.  Participants will be given a copy of the signed consent document for their own records.  If you 
do not want to release your health information, you may not want to take part in this clinical trial (do not 
sign this form if you do not want to take part in this clinical trial, or you do not want to release your 
health information). 
 
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study or a research-related injury contact Elizabeth Turcotte via phone 
(207.795.2134) or email (TurcotEl@cmhc.org). 
 
For questions about your rights as a research participant, contact the Central Maine Medical Center 
Institutional Review Board (which is a group of people who review the research to protect your rights) at 
(207) 795-2176.  Deborah Taylor, Ph.D. is the chairperson of the Central Maine Medical Center 
Institutional Review Board. 
 
COMPENSATION 
Participants in this study will not receive any compensation if the results of the research are used towards 
the development of a commercially available product. 
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A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by 
U.S. Law.  This Web site will not include information that can identify you.  At most, the Web site 
will include a summary of the results.  You can search this site at any time pursuant to 21 CFR 
50.25(C).  For applicable clinical trials as defined in 42 U.S.C. 282(j)(1)(A). 
 
You have read, or have had read to you, the above information before signing this consent form.  You agree to 
participate in this clinical trial.  You also authorize you your permission to use or disclose your personal health 
information for the purpose of this research.  You have been offered ample opportunity to ask questions and have 
received answers that fully satisfy those questions. 
 
I have agreed to participate in this research project.  I understand the purpose of the procedure(s) and the 
risks/benefits involved in its performance. 
 
________________________________________  _________________ 
Signature of Participant or guardian      Date 
 
 
________________________________________ 
Printed Name of Participant or guardian 
 
 
I have fully explained to  _________________the nature and purpose of the above-described procedure 
and the risks/benefits involved in its performance.  I have answered and will answer all questions to the 
best of my ability.  I will inform the subject of any changes in the procedure or the risks and benefits if 
any should occur during or after the course of the study. 
 
___________________________________________  _________________ 
Signature of person obtaining consent     Date 
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Appendix E 
Approval Letter 
 
